Spectral Capital Ties Its Offering to Nasdaq Uplisting Requirements

There is a sentence in Spectral Capital Corporation’s late-August announcement that captures the logic of many OTC-to-exchange transactions. The company said it would not proceed with its offering if its common stock was not approved for listing on the Nasdaq Capital Market. The capital raise and the uplisting were, by design, one event.

Spectral Capital, a Nevada corporation whose shares trade on the OTCQB under the symbol FCCN, described the plan in a press release filed with a Form 8-K on August 25, 2026. It had applied to list on the Nasdaq Capital Market under the same symbol, and its registration statement on Form S-1, which EDGAR records show it filed in July, was not yet effective.

The proposed deal

The release set out the terms:

• An offering of up to $15,000,000
• An expected price range of $4.00 to $5.00 per share
• 100,624,749 shares outstanding after the offering, or 101,124,749 if the over-allotment option is exercised in full
• A 180-day lock-up for officers, directors and holders of 5% or more after closing

The company was careful about uncertainty. It said there was no assurance that Nasdaq would approve the listing or that an active trading market would develop.

Why the conditional structure exists

Nasdaq’s uplisting requirements set a series of entry thresholds. Among them are a minimum bid price, minimum stockholders’ equity or market value standards, a minimum number of unrestricted publicly held shares with a minimum market value, a minimum number of round-lot shareholders, and governance requirements including an independent audit committee.

An OTC company with a modest float often cannot satisfy every one of those tests on its own. An offering that closes concurrently with listing can supply new holders, new equity and an offering price that sets the initial market value. That is why underwriters and issuers commonly make the offering conditional on approval: if the exchange says no, the economics of the deal and the investor base it was designed to create fall away.

The condition protects everyone in the deal from the same risk: buying OTC stock at an exchange price.

The numbers in the release

Spectral Capital’s release also offered an operating snapshot for the first half of 2026: $646.7 million in revenue, $5.47 million in gross profit and roughly 335 enterprise customers. The gap between those revenue and gross profit figures implies a very thin gross margin, under 1%, which readers would want explained in the full registration statement.

Who is affected

Current OTCQB holders face both opportunity and dilution. A Nasdaq listing could widen the buyer base and improve liquidity, but new shares issued in the offering expand the share count. Insiders and large holders are bound by the lock-up for 180 days after closing. Prospective investors must rely on the S-1 prospectus for the full financial statements and risk factors.

Uplisting requirements as a timeline

The conditional structure also sets the order of events. The SEC must declare the S-1 effective. Nasdaq must approve the listing. Only then can pricing and closing occur. A delay at any step pushes back the others.

Taken together, the sequence shows how an OTC company’s path to an exchange depends on several independent approvals lining up. The SEC reviews the disclosure, Nasdaq reviews the listing qualifications, and the market sets the final price.

What to watch

Readers should watch for an S-1 amendment and notice of effectiveness, a Nasdaq approval announcement, final pricing within or outside the $4.00 to $5.00 range, and the first full set of audited financials explaining the company’s revenue and margin profile.